Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide (Q43180130)

15 November 2017

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide (English)

1 reference

15 November 2017

1 reference

3

Michaela Diamant

1 reference

15 November 2017

Renate E van Genugten

series ordinal

1

1 reference

PubMed ID

20115929

15 November 2017

Daniël H van Raalte

series ordinal

2

1 reference

15 November 2017

1 December 2009

1 reference

Diabetes Research and Clinical Practice

15 November 2017

1 reference

15 November 2017

86 Suppl 1

1 reference

15 November 2017

S26-34

1 reference

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

15 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Mechanisms of action of glucagon-like peptide 1 in the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Causes and metabolic consequences of Fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2809%2970006-3

7 January 2021

10.1016/S0168-8227(09)70006-3

Identifiers

DOI

1 reference

15 November 2017

1 reference

PubMed ID

20115929